Asimov Press • 786 implied HN points • 27 Feb 26
- Better AI-designed molecules won't automatically make clinical trials faster, because timelines are set by human biology, patient recruitment, logistics, and regulatory processes that take real calendar time.
- Clinical trials do two jobs—validation and learning—and AI needs rich human trial data to improve; many important outcomes, especially for chronic diseases and aging, take years to observe so trials remain slow even with better drugs.
- Real acceleration requires institutional and regulatory reforms—like validated surrogate endpoints, streamlined review pathways, and better data sharing—because AI alone can only improve trials at the margins until those systems change.